“Drugs in the COVID-19 pandemic: Analysis of the commercialization of azithromycin, hydroxychloroquine, ivermectin and nitazoxanide in Brazil”, RSD, vol. 11, no. 6, p. e16711628726, Apr. 2022, doi: 10.33448/rsd-v11i6.28726.